357 related articles for article (PubMed ID: 19057237)
1. Polypharmacy with second-generation antipsychotics: a review of evidence.
Pandurangi AK; Dalkilic A
J Psychiatr Pract; 2008 Nov; 14(6):345-67. PubMed ID: 19057237
[TBL] [Abstract][Full Text] [Related]
2. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
[TBL] [Abstract][Full Text] [Related]
4. A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness.
Megna JL; Kunwar AR; Mahlotra K; Sauro MD; Devitt PJ; Rashid A
J Psychiatr Pract; 2007 Mar; 13(2):129-37. PubMed ID: 17414692
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of the efficacy of second-generation antipsychotics.
Davis JM; Chen N; Glick ID
Arch Gen Psychiatry; 2003 Jun; 60(6):553-64. PubMed ID: 12796218
[TBL] [Abstract][Full Text] [Related]
6. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
[TBL] [Abstract][Full Text] [Related]
7. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making.
Volavka J; Citrome L
Expert Opin Pharmacother; 2009 Aug; 10(12):1917-28. PubMed ID: 19558339
[TBL] [Abstract][Full Text] [Related]
8. Polypharmacy prevalence rates in the treatment of unipolar depression in an outpatient clinic.
Glezer A; Byatt N; Cook R; Rothschild AJ
J Affect Disord; 2009 Sep; 117(1-2):18-23. PubMed ID: 19103462
[TBL] [Abstract][Full Text] [Related]
9. Polypharmacy in schizophrenia.
Zink M; Englisch S; Meyer-Lindenberg A
Curr Opin Psychiatry; 2010 Mar; 23(2):103-11. PubMed ID: 20051861
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic polypharmacy in patients with schizophrenia in a brief hospitalization unit.
Lerma-Carrillo I; de Pablo Brühlmann S; del Pozo ML; Pascual-Pinazo F; Molina JD; Baca-García E
Clin Neuropharmacol; 2008; 31(6):319-32. PubMed ID: 19050409
[TBL] [Abstract][Full Text] [Related]
11. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies.
Zuddas A; Zanni R; Usala T
Eur Neuropsychopharmacol; 2011 Aug; 21(8):600-20. PubMed ID: 21550212
[TBL] [Abstract][Full Text] [Related]
12. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
Constantine RJ; Andel R; McPherson M; Tandon R
Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
[TBL] [Abstract][Full Text] [Related]
14. Antipsychotic polypharmacy or monotherapy?
Gardos G
Neuropsychopharmacol Hung; 2005 Jun; 7(2):72-7. PubMed ID: 16167458
[TBL] [Abstract][Full Text] [Related]
15. A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia.
Suzuki T; Uchida H; Watanabe K; Yagi G; Kashima H
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):361-9. PubMed ID: 14751434
[TBL] [Abstract][Full Text] [Related]
16. [Polypharmacy in the treatment of schizophrenia].
Messer T; Tiltscher C; Schmauss M
Fortschr Neurol Psychiatr; 2006 Jul; 74(7):377-91. PubMed ID: 16804806
[TBL] [Abstract][Full Text] [Related]
17. [Is it valid to concurrently use multiple antipsychotics for patients with schizophrenia?].
Suzuki T; Watanabe K; Yagi G; Kashima H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2005 Aug; 25(4):159-68. PubMed ID: 16190364
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment with amisulpride in patients with schizophrenia discharged from a short-term hospitalization unit: a 1-year retrospective study.
Molina JD; Lerma-Carrillo I; Leonor M; Pascual F; Blasco-Fontecilla H; González-Parra S; López-Muñoz F; Alamo C
Clin Neuropharmacol; 2009; 32(1):10-5. PubMed ID: 18978498
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness of guideline implementation strategies on improving antipsychotic medication management for schizophrenia.
Owen RR; Hudson T; Thrush C; Thapa P; Armitage T; Landes RD
Med Care; 2008 Jul; 46(7):686-91. PubMed ID: 18580387
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic medication utilization trends among Texas veterans: 1997-2002.
Yang M; Barner JC; Lawson KA; Rascati KL; Wilson JP; Crismon ML; Worchel J; Mascarenas CA
Ann Pharmacother; 2008 Sep; 42(9):1229-38. PubMed ID: 18682544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]